New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions

(MedPage Today) -- MADRID -- Amivantamab (Rybrevant) confirmed its clinical benefit in advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions, and in doing so has established a new first-line standard for this patient population...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news